OrsoBio Unveils Promising Data on Mitochondrial Protonophores at ADA 2026
OrsoBio to Present Preclinical and Clinical Data from its Mitochondrial Protonophore Portfolio at the American Diabetes Association's 2026 Scientific Sessions
Benzinga
Image: Benzinga
OrsoBio, Inc. will present new clinical and preclinical data at the 2026 American Diabetes Association Scientific Sessions in New Orleans, highlighting the benefits of mitochondrial protonophores TLC-6740 and TLC-1180 for obesity treatment, including enhanced weight loss and improved insulin sensitivity.
- 01TLC-6740 combined with tirzepatide resulted in an average of 4.5% greater weight loss compared to tirzepatide alone in a Phase 2a study.
- 02TLC-1180 demonstrated significant improvements in insulin sensitivity and exercise capacity in diet-induced obese mice, achieving a 140% increase in whole-body insulin sensitivity.
- 03TLC-1180 also mitigated cognitive decline in obese mice, restoring neuronal activity in brain regions associated with cognition.
- 04Both TLC-6740 and TLC-1180 are designed to enhance energy expenditure and improve metabolic health without significant safety concerns.
- 05OrsoBio aims to position mitochondrial protonophores as a new therapeutic class for obesity and related metabolic disorders.
Advertisement
In-Article Ad
OrsoBio, Inc., a biopharmaceutical company focused on obesity treatments, is set to present new findings at the 2026 American Diabetes Association Scientific Sessions in New Orleans from June 5-8, 2026. The data includes clinical results from a Phase 2a study of TLC-6740, which, when combined with tirzepatide, led to a significant 4.5% increase in weight loss compared to tirzepatide alone. The study also showed improvements in insulin sensitivity and liver health, with TLC-6740 being well-tolerated. Additionally, preclinical data for TLC-1180 revealed its potential to enhance exercise capacity and insulin sensitivity in diet-induced obese mice, achieving a remarkable 140% improvement in whole-body insulin sensitivity. TLC-1180 also demonstrated cognitive benefits by reversing obesity-associated cognitive decline in mice. OrsoBio's CEO, Mani Subramanian, emphasized the innovative approach of targeting mitochondrial protonophores to address multiple aspects of obesity-related diseases, aiming to unlock broader health benefits.
Advertisement
In-Article Ad
The findings from OrsoBio could significantly influence treatment options for obesity and related metabolic disorders, potentially improving health outcomes for individuals affected by these conditions.
Advertisement
In-Article Ad
Reader Poll
How do you feel about the potential of mitochondrial protonophores in obesity treatment?
Connecting to poll...
Read the original article
Visit the source for the complete story.